FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Study protocol: randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs. immediate surgery and adjuvant chemotherapy for localized soft tissue sarcoma: Japan Clinical Oncology Group study JCOG2102 (NACLESS). PMID 39500618 · Jpn J Clin Oncol · 2025-Mar-05 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The Hypotension Prediction Index in Free Flap Transplant in Head and Neck Surgery: Protocol of a Prospective Randomized Controlled Trial. PMID 40141745 · Life (Basel) · 2025-Mar-04 The record is a protocol for a randomized trial in oncology patients (head and neck cancer surgery), but it evaluates a monitoring technology (Hypotension Prediction Index) against standard care for intraoperative hypotension, not a drug intervention. The primary endpoint is a hemodynamic measure (time-weighted average MAP), not a time-to-event efficacy outcome like OS/PFS. It is a protocol without reported results, and the trial phase is not specified as definitive (Phase III/IIIb or II/III). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trial. PMID 40042985 · Br J Surg · 2025-Mar-04 The trial meets oncology, human, randomized, time-to-event, and original-result criteria. However, it fails the drug-intervention criterion because the comparison is surgical (axillary surgery vs. no-axillary staging). Furthermore, the trial phase is not confirmed as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers. PMID 40038236 · Cell Death Dis · 2025-Mar-04 The record is a preclinical and retrospective analysis study, not an original formal-result report of a randomized trial. While it references a phase III study, the abstract does not describe the trial's results in terms of time-to-event endpoints (OS, PFS, etc.) or survival analysis methods. It focuses on biomarker analysis (PD-L1, tumor size) and mechanisms of immune checkpoint blockade response. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial. PMID 39847361 · JAMA · 2025-Mar-04 干预为非药物单独策略,未满足药物干预要求。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. PMID 39556242 · Circulation · 2025-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effectiveness of systemic heparin during arteriovenous fistula creation by emulating a target trial. PMID 38825327 · Am J Epidemiol · 2025-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Growth Response to Weekly Somapacitan Therapy in Children With GH Deficiency Is Related to GH Thresholds in GH Stimulation Testing. PMID 40104568 · J Endocr Soc · 2025-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial. PMID 40085084 · JAMA Netw Open · 2025-Mar-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. PMID 40080017 · JAMA Netw Open · 2025-Mar-03 This is a secondary analysis of healthcare burden in phase 3 randomized oncology trials, not a report of primary/time-to-event efficacy results for a drug intervention. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Somatic acupressure for the management of the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a study protocol for a phase III randomised controlled trial. PMID 40032405 · BMJ Open · 2025-Mar-03 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China. PMID 40032375 · BMJ Open · 2025-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. PMID 40029660 · JAMA Netw Open · 2025-Mar-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. PMID 39947918 · J Nucl Med · 2025-Mar-03 The record describes a Phase III randomized trial (NETTER-1) but this specific publication is a dosimetry/toxicity substudy. It is not randomized (the substudy itself does not randomize), and the primary efficacy endpoint is not time-to-event (no OS/PFS/DFS/etc. reported; only exploratory tumor size changes and dosimetry results). Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer. PMID 39945807 · JNCI Cancer Spectr · 2025-Mar-03 The record is excluded because it is not an original result report of a single Phase III or Phase II/III randomized trial. It is a meta-analytical or observational study that synthesizes results from multiple trials to assess real-world effectiveness, thus failing the 'original_result' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial. PMID 39786436 · Clin Cancer Res · 2025-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19. PMID 40025095 · NPJ Vaccines · 2025-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors. PMID 40024914 · Cancer Immunol Immunother · 2025-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of a submucosal and subserosal approach in ICG-guided laparoscopic lymphadenectomy in gastric cancer patients: long-term outcomes of a phase 3 randomized clinical trial. PMID 39903562 · Int J Surg · 2025-Mar-01 干预为非药物单独策略,未满足药物干预要求。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Neuromodulation for Children With Hemiparesis and Perinatal Stroke: A Randomized Clinical Trial. PMID 39899326 · JAMA Neurol · 2025-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. PMID 39878970 · JAMA Dermatol · 2025-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of virtual reality intervention on hospitalized patients with acute pain after thoracoscopic surgery: a pilot randomized clinical trial. PMID 39878180 · Int J Surg · 2025-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. PMID 39804640 · JAMA Neurol · 2025-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial. PMID 39786764 · JAMA Oncol · 2025-Mar-01 The study is a randomized clinical trial with oncology focus and a time-to-event efficacy endpoint (overall survival), but it does not involve a drug-containing intervention; the intervention is a shared care model. Therefore, it does not meet the criterion of a drug-containing intervention required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial. PMID 39745682 · JAMA Oncol · 2025-Mar-01 The study is a Phase III oncology trial with drug intervention and time-to-event endpoints, but it is explicitly described as nonrandomized, which fails a key eligibility criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial. PMID 39693081 · JAMA Psychiatry · 2025-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study. PMID 39692332 · Dermatol Surg · 2025-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. PMID 39659157 · Am J Psychiatry · 2025-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial. PMID 39501485 · Int J Cancer · 2025-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial. PMID 39353477 · Int J Radiat Oncol Biol Phys · 2025-Mar-01 This is a primary report of a Phase III randomized trial in oncology with a drug-containing intervention (chemotherapy), but its primary endpoint is safety/toxicity, not a time-to-event efficacy endpoint (e.g., OS, PFS). The abstract confirms efficacy outcomes are not yet reported. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery. PMID 39045699 · Ann Surg · 2025-Mar-01 The study is a randomized trial in oncology with time-to-event endpoints, but the intervention is a non-drug perioperative management strategy, not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Sugammadex Versus Neostigmine Reversal on Postoperative Recovery Time in Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial. PMID 38848257 · Anesth Analg · 2025-Mar-01 The study is a randomized controlled trial in human patients with a drug intervention (sugammadex vs neostigmine). However, it is a non-oncology study focusing on postoperative recovery in bariatric surgery patients with obstructive sleep apnea, and its primary and secondary endpoints are not time-to-event efficacy outcomes (OS, PFS, DFS, etc.) but rather recovery time metrics (OR discharge time, eye opening time, extubation time). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones. PMID 40248297 · Eur Heart J Suppl · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis. PMID 40243852 · Arq Bras Cardiol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Tislelizumab in Lung Cancer Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 40230743 · Cureus · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. PMID 40225393 · Kidney Int Rep · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). PMID 40221173 · Gynecol Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Single-dose vs prolonged antibiotic prophylaxis of fosfomycin for transrectal prostate biopsy: a single-center prospective, randomized, controlled trial. PMID 40213351 · Prostate Int · 2025-Mar The study is a randomized controlled trial evaluating antibiotic prophylaxis for prostate biopsy, not a treatment trial for human malignant neoplasm. While it involves a drug and reports original results, it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) and is not in the context of cancer treatment. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-inflammatory potential of royal jelly in multiple sclerosis disease: a double randomized clinical trial. PMID 40213172 · Ann Med Surg (Lond) · 2025-Mar The study is a randomized clinical trial in humans with original results, but it is not an oncology study, the intervention is not a drug, and the primary endpoints are not time-to-event efficacy measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The curative potential of stereotactic radiotherapy in oligometastatic colorectal cancer: a narrative review. PMID 40211742 · Ann Palliat Med · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis. PMID 40163534 · PLoS Med · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison between opioid-based anaesthesia technique and opioid-free anaesthesia technique in patients undergoing laparotomy for gynaecological malignancy: A randomised controlled trial. PMID 40161920 · Indian J Anaesth · 2025-Mar Eligibility requires an explicit time-to-event efficacy endpoint (e.g., OS, PFS) for a drug intervention in a Phase III/IIIb or Phase II/III randomized trial. This study is a randomized trial in oncology patients but evaluates perioperative anesthetic techniques, not a systemic drug's efficacy on cancer survival or progression endpoints. It lacks the required time-to-event outcome and definitive phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Buffered salt solution versus 0.9% sodium chloride as fluid therapy for patients presenting with moderate to severe diabetic ketoacidosis: Study protocol for a Phase-3 cluster-crossover, blinded, randomised, controlled trial. PMID 40160240 · Crit Care Resusc · 2025-Mar 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| [Sublobar resection in early-stage NSCLC: towards a new therapeutic standard?]. PMID 40155073 · Bull Cancer · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India. PMID 40127383 · JCO Glob Oncol · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Letter to the editor in response to a letter by Fuchs and Santosham regarding; assessing safety and efficacy of a novel glucose-free amino acid oral rehydration solution for watery diarrhea management in children: a randomized, controlled, phase III trial. PMID 40115172 · EClinicalMedicine · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial. PMID 40111739 · CNS Drugs · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial. PMID 40111738 · CNS Drugs · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials. PMID 40086043 · Diabetes Metab Syndr · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial. PMID 40056850 · ESMO Open · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |